Intervention

Loperamide

ClinicalTrials.gov intervention label

Clinical trials14
Recruiting3
Common conditions25
Lead sponsors shown12

Clinical trials

14 shown
Rash & Diarrhea Prophylaxis With CapivasertibNCT07426822 · 2026-08-15
RECRUITING
Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer PatientsNCT06892093 · 2025-08-07
RECRUITING
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer PatientsNCT04038619 · 2021-02-01
RECRUITING
Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMEDNCT05520723 · 2023-02-06
COMPLETED
Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant NeratinibNCT05252988 · 2022-08-31
ACTIVE_NOT_RECRUITING
Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy SubjectsNCT05252546 · 2022-03-08
COMPLETED
A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With NeratinibNCT04366713 · 2020-06-30
COMPLETED
Prevention and Treatment of Pyrrolitinib-associated DiarrheaNCT04736186 · 2020-05-16
UNKNOWN
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced MalignanciesNCT04172597 · 2019-12-23
TERMINATED
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and NeratinibNCT03094052 · 2018-10-09
COMPLETED
A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast CancerNCT02441946 · 2015-08-01
COMPLETED
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and LoperamideNCT02400476 · 2015-02-01
COMPLETED
Pilot Study to Assess Dimethyl Fumarate Related GI Symptom MitigationNCT02217982 · 2014-07-01
TERMINATED
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has SpreadNCT02057133 · 2014-03-10
ACTIVE_NOT_RECRUITING

Common conditions

Breast Cancer5HER2-positive Breast Cancer2Advanced HR+/HER2- Breast Cancer1Breast Adenocarcinoma1Breast Neoplasms1Cervical Cancer1Colitis1Colorectal Cancer1Diarrhea1Diarrhea Caused by Drug1Early Stage HER2+ Breast Cancer1Early-stage Breast Cancer1Early-Stage Breast Carcinoma1Glioblastome Multiforme1HER2 Amplified Breast Cancer1HER2 Positive Breast Cancer1HER2-positive Recurrent / Metastatic Breast Cancer1Hormone Receptor Positive1Hormone Receptor Positive Tumor1Lung Cancer1Malignant Genitourinary System Neoplasm1Melanoma1Metastatic HR+/HER2- Breast Cancer1Neratinib1Ovarian Cancer1

Trial status mix

COMPLETED6
RECRUITING3
ACTIVE_NOT_RECRUITING2
TERMINATED2
UNKNOWN1

Phase mix

PHASE29
PHASE13
NA1
PHASE31
PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.